TABLE 2.
Cancer Characteristics
| Non-TRKi (n = 27) | TRKi (n = 28) | All (N = 55) | |
|---|---|---|---|
| Cancer type, n (%) | |||
| Brain | 2 (7) | 5 (18) | 7 (13) |
| Astrocytoma | 1 (50) | 0 (0) | 1 (14) |
| Glioblastoma multiforme | 0 (0) | 5 (100) | 5 (71) |
| Oligodendroglioma | 1 (50) | 0 (0) | 1 (14) |
| Breast, ductal | 3 (11) | 0 (0) | 3 (5) |
| Colorectal, adenocarcinoma | 4 (15) | 2 (7) | 6 (11) |
| Endometrial, adenocarcinoma/endometrioid | 0 (0) | 1 (4) | 1 (2) |
| Gastric, adenocarcinoma | 1 (4) | 0 (0) | 1 (2) |
| Salivary gland | 3 (11) | 5 (18) | 8 (15) |
| Salivary gland | 1 (33) | 4 (80) | 5 (62) |
| Acinic cell carcinoma | 0 (0) | 2 (50) | 2 (40) |
| Mammary analogue secretory carcinoma | 0 (0) | 1 (25) | 1 (20) |
| Secretory carcinoma | 1 (100) | 0 (0) | 1 (20) |
| Unknown | 0 (0) | 1 (25) | 1 (20) |
| Parotid Gland | 2 (67) | 0 (0) | 2 (25) |
| Unknown | 0 (0) | 1 (20) | 1 (12) |
| Lung, non–small cell | 2 (7) | 5 (18) | 7 (13) |
| Adenocarcinoma | 1 (50) | 3 (60) | 4 (57) |
| Large-cell carcinoma | 1 (50) | 0 (0) | 1 (14) |
| Squamous cell carcinoma | 0 (0) | 1 (20) | 1 (14) |
| Poorly differentiated NSCLC NOS | 0 (0) | 1 (40) | 1 (14) |
| Melanoma | 3 (11) | 0 (0) | 3 (5) |
| Superficial spreading | 1 (33) | 0 (0) | 1 (33) |
| Favor atypical spitz tumor | 1 (33) | 0 (0) | 1 (33) |
| Unknown | 1 (33) | 0 (0) | 1 (33) |
| Ovarian | 0 (0) | 2 (7) | 2 (4) |
| Epithelial cancer | 0 (0) | 1 (50) | 1 (50) |
| Unknown | 0 (0) | 1 (50) | 1 (50) |
| Pancreatic | 1 (4) | 0 (0) | 1 (2) |
| Prostate, adenocarcinoma | 1 (4) | 0 (0) | 1 (2) |
| Sarcoma, soft-tissue | 3 (11) | 2 (7) | 5 (9) |
| Liposarcoma | 1 (33) | 0 (0) | 1 (20) |
| Malignant peripheral nerve sheath tumor | 1 (33) | 0 (0) | 1 (25) |
| Infantile fibrosarcoma | 0 (0) | 1 (50) | 1 (25) |
| Mullerian adenosarcoma | 0 (0) | 1 (50) | 1 (25) |
| Uterine leiomyosarcoma | 1 (33) | 0 (0) | 1 (25) |
| Thyroid | 3 (11) | 5 (18) | 8 (15) |
| Papillary | 3 (100) | 4 (80) | 7 (88) |
| Unknown | 0 (0) | 1 (20) | 1 (12) |
| Other | 1 (4) | 1 (4) | 2 (4) |
| Adnexal adenocarcinoma of skin | 1 (100) | 0 (0) | 1 (50) |
| Neuroblastoma | 0 (0) | 1 (100) | 1 (50) |
| Stage at cancer diagnosis, n (%) | |||
| I | 8 (30) | 5 (19) | 13 (24) |
| II | 4 (15) | 3 (11) | 7 (13) |
| III | 6 (22) | 5 (19) | 11 (20) |
| IV | 7 (26) | 11 (41) | 18 (33) |
| Unknown | 2 (7) | 3 (11) | 5 (9) |
| Stage at NTRK testing, n (%) | |||
| I | 4 (15) | 1 (4) | 5 (9) |
| II | 3 (11) | 1 (4) | 4 (7) |
| III | 4 (15) | 4 (14) | 8 (15) |
| IV | 16 (59) | 19 (68) | 35 (64) |
| Unknown | 0 (0) | 3 (11) | 3 (5) |
| Stage at TRKi initiation, n (%) | |||
| I | NA | 1 (4) | NA |
| II | NA | 1 (4) | NA |
| III | NA | 3 (11) | NA |
| IV | NA | 20 (71) | NA |
| Unknown | NA | 3 (11) | NA |
| ECOG performance score at initial cancer diagnosis, n (%) | |||
| 0 | 13 (48) | 14 (50) | 27 (49) |
| 1 | 6 (22) | 9 (32) | 15 (27) |
| 2 | 2 (7) | 2 (7) | 4 (7) |
| Unknown | 6 (22) | 3 (11) | 9 (16) |
| Site of metastases, n (%) | |||
| Lung | 5 (19) | 10 (36) | 15 (27) |
| Liver | 4 (15) | 8 (29) | 12 (22) |
| Brain | 5 (19) | 4 (14) | 9 (16) |
| Bone | 5 (19) | 7 (25) | 12 (22) |
| Other | 9 (33) | 9 (32) | 18 (33) |
| None | 9 (33) | 6 (21) | 15 (27) |
ECOG = Eastern Cooperative Oncology Group; NSCLC NOS = non–small cell lung cancer not otherwise specified; NTRK = neurotrophic tyrosine receptor kinase; TRKi = tyrosine receptor kinase inhibitor.